Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial
| العنوان: | Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial |
|---|---|
| المؤلفون: | Mei Dong, Huiqun Song, Yan Pan, Bing Li, Bo Gao, Qi Chen, Jiazhen Li, Chuanyu Liu, Wenzheng Chu, Hongliang Wu, Lianwei Dou, Lixiang Song |
| المصدر: | BMC Neurology, Vol 20, Iss 1, Pp 1-8 (2020) BMC Neurology |
| بيانات النشر: | BMC, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Heterozygote, CYP2C19, Transient ischaemic attacks, lcsh:RC346-429, Cerebral artery stenosis, Internal medicine, Diabetes mellitus, Carotid stenosis, Medicine, Humans, cardiovascular diseases, Ischaemic stroke, lcsh:Neurology. Diseases of the nervous system, Aged, Ischemic Stroke, Aspirin, Dose-Response Relationship, Drug, business.industry, Hazard ratio, General Medicine, Middle Aged, medicine.disease, Clopidogrel, Cytochrome P-450 CYP2C19, Stenosis, Dual antiplatelet aggregation therapy, Treatment Outcome, Cardiology, Female, Neurology (clinical), Intracranial stenosis, business, Platelet Aggregation Inhibitors, medicine.drug, Research Article |
| الوصف: | Background Dual antiplatelet aggregation therapy leads to better outcomes in patients with carotid artery stenosis, intracranial artery stenosis, minor strokes, or transient ischaemic attacks. However, carriers of the CYP2C19 loss-of-function allele may not experience the desired effects. We attempted to increase the clopidogrel dose to determine whether it would improve the outcomes of stroke patients who carry a single loss-of-function allele. Methods We recruited 131 patients with minor ischaemic stroke, within less than 7 days of stroke onset and a CYP2C19 loss-of-function allele, who had moderate-to-severe cerebral artery stenosis. Patients were divided into the high dose group (clopidogrel 150 mg per day + aspirin 100 mg per day over 21 days.) and a normal dose group (clopidogrel 75 mg per day + aspirin 100 mg per day over 21 days). The reported outcomes included any vascular or major bleeding events as the primary and safety endpoints, respectively. Results One and six vascular events occurred in the high dose and normal dose groups during the 3-months follow-up period, respectively. However, no significant difference was found between the two groups when adjusted for history of diabetes (hazard ratio, 5482; 95% confidence interval, 0.660 to 45.543; P = 0.115). No major bleeding events occurred. Conclusions In patients with ischaemic stroke who had a single CYP2C19 loss-of-function allele and moderate to severe cerebral stenosis, fewer vascular events occurred within 3 months with high dose of clopidogrel and aspirin than with normal dose of clopidogrel and aspirin. However, the difference between the two groups was not significant. Trial registration Clinical study of clopidogrel in the treatment of patients with symptomatic moderate to severe cerebral artery stenosis with intermediate metabolites of CYP2C19, URL: http://www.chictr.org.cnTest/. Unique identifier: ChiCTR1800017411, 07/28/2018 |
| اللغة: | English |
| تدمد: | 1471-2377 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba32d43bd4d97a2d428398c5aff79215Test http://link.springer.com/article/10.1186/s12883-020-01974-zTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....ba32d43bd4d97a2d428398c5aff79215 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14712377 |
|---|